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Treatment Outcomes for Hepatoblastoma: Experience
of 35 Cases at a Single Institution
Pei-Kwei Tsay,1 Jin-Yao Lai,2 Chao-Ping Yang,3 Iou-Jih Hung,3 Chuen Hsueh,4
Ming-Horng Tsai,3 Tang-Her Jaing3*
Background/Purpose: Hepatoblastoma is the most common malignant liver tumor in children. Comparative
studies have elucidated the optimal pre- or postoperative chemotherapeutic regimens. The aim of this
study was to investigate the prognostic significance of baseline tumor characteristics for overall survival
and disease-free survival in children with hepatoblastoma.
Methods: There were 19 male and 16 female children with a median age of 19 months at diagnosis
(range: 1–169 months) in our institution between February 1990 and June 2009. We reviewed the clinical
presentation, serum α-fetoprotein level at diagnosis, histological subtype, treatment, and outcomes.
Results: Twenty-seven patients (78%) underwent neoadjuvant chemotherapy. The majority of patients
subsequently underwent either hemihepatectomy (56%) or bisegmentectomy (16%). Only six patients
underwent extended hepatic resection, and one of them required rescue liver transplantation. During 
follow-up, six patients died of progressive disease and two of perioperative mortality. Four of the six 
who died had pulmonary metastases at the time of diagnosis or follow-up. The median survival time was
28 months (range: 1–181 months). Five-year overall survival was 67.7% (95% confidence interval:
52.0–87.8%) and disease-free survival was 60.2% (95% confidence interval: 41.9–86.5%).
Conclusion: The potential down-staging effect of neoadjuvant chemotherapy on hepatoblastoma might
facilitate remission and convert unresectable tumors into operable ones.
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Hepatoblastoma accounts for 79% of all liver 
tumors in children and almost two-thirds of 
primary malignant liver tumors in the pediatric
age group. Surgical resection is the cornerstone
of treatment for patients with hepatoblastoma.1
Chemotherapy is used to reduce tumor size in 
lesions that appear unresectable at diagnosis and
to control residual microscopic disease after de-
finitive resection.2 More recently, data from the
International Childhood Liver Tumour Strategy
Group (SIOPEL), which uses neoadjuvant chemo-
therapy, have demonstrated overall survival rates
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as high as 89% and event-free survival rates as
high as 80%.3 The objective of this study was to
assess the assumed surgical advantages of neoad-
juvant chemotherapy.
Subjects and Methods
Our objective was to review the experience of a
leading tertiary referral center in treating hepato-
blastoma in children over the past 19 years. We
studied a cohort of 35 children with hepatoblas-
toma managed in our institution between February
1990 and June 2009. There were 19 male and 16
female children with a median age of 19 months
at diagnosis (range: 1–169 months). The diag-
nosis was confirmed histologically in 32 of the
35 patients. The remaining three patients with
age of onset between 13 and 30 months were di-
agnosed with hepatoblastoma based on serum
α-fetoprotein (AFP) levels without histopatho-
logical confirmation, and obvious tumor regres-
sion after chemotherapy confirmed the diagnosis.
One patient with a history of extremely low birth
weight developed hepatoblastoma at the age of 
2 years.
Recurrence was identified from unequivocal
imaging and serially increasing AFP levels or biopsy
confirmation. Kaplan–Meier survival analysis was
conducted to determine actuarial survival. Ninety-
five percent confidence intervals (CIs) were cal-
culated for the survival estimation. The study was
duly approved by the Faculty Ethics Committee.
Written informed consent was obtained from
parents or the legal guardian before each medical
intervention.
Results
A palpable mass in the abdomen was the present-
ing symptom in 30 patients (85.7%). The median
AFP level at diagnosis was 205,000 ng/mL (range:
467–2,420,000ng/mL). Of those 35 patients, seven
had documented pulmonary metastasis. Initial
lung metastasis developed in four patients (11.4%).
Chemotherapy regimens included the SIOPEL
study protocols.
Thirty-one patients underwent surgical resec-
tion. Four patients underwent primary surgery,
and 27 patients underwent delayed surgery after
super-PLADO chemotherapy. The regimen con-
sisted of alternating cycles of 80 mg/m2 cisplatin
over 24 hours, 60 mg/m2 doxorubicin over 48
hours, and 500 mg/m2 carboplatin over 1 hour.
Thirteen patients (40%) underwent right hepate-
ctomy; five (16%) had left hepatectomy; eight
(25%) had right extended hepatectomy; one (3%)
had left extended hepatectomy; and five (16%)
had bisegmentectomy. One patient subsequently
required rescue liver transplantation for residual
disease.
As shown in the Table, the post-chemotherapy
histological types encountered as per the SIOPEL
Table. Summary of selected clinical data and
histopathological characteristics of patients
with hepatoblastoma
Characteristics Value 
Sex
Male 19
Female 16
Age (mo)
Median 19
Range 1–169
Serum α-fetoprotein (ng/L) 467–2,420,000
Pulmonary metastasis
At diagnosis 4
Follow-up after diagnosis 2
Surgery
Primary surgery 4
Delayed surgery (post-PLADO)* 27
Histotype
Epithelial 14
Pure fetal 1
Embryonal/fetal 12
Macrotrabecular 1
Epithelial/mesenchymal 18
Not teratoid 16
Teratoid 2
*Alternating cycles of 80 mg/m2 cisplatin over 24 hours, 60 mg/m2
doxorubicin over 48 hours, and 500mg/m2 carboplatin over 1 hour.
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Liver Study Group4 were as follows: purely fetal
type – 1; embryonal and mixed embryonal/fetal
subtype – 12; macrotrabecular subtype – 1; mixed
epithelial and mesenchymal type without tera-
toid features – 16; and mixed epithelial and mes-
enchymal type with teratoid features – 2. Two
patients died during the perioperative period. Six
patients died of progressive disease, and four 
of them had pulmonary metastases at the time 
of diagnosis or follow-up. The presence of pul-
monary metastases might be a predictor of poor
prognosis.
Although there were three recurrences, two
patients had distant metastasis to the lung and
one was local. The median survival time was 36
months (range: 1–181 months), and 5-year over-
all survival and disease-free survival rates were
67.7% (95% CI: 52.0–87.8%) and 60.2% (95%
CI: 41.9–86.5%), respectively (Figure).
Discussion
Considerable controversy has surrounded the dis-
crepancy between United States and international
hepatoblastoma therapeutic protocols; surgery and
staging are initially advised in the United States,
whereas adjuvant therapy is strongly considered
internationally.5 Therefore, neoadjuvant chemo-
therapy followed by resection has become the
mainstay in the treatment of hepatoblastoma.6–8
With very effective preoperative chemotherapy
for hepatoblastoma, many tumors can be shrunk
to permit partial hepatectomy.9 Total hepatec-
tomy and liver transplantation has emerged as
an effective treatment for the small proportion of
children with unresectable hepatoblastoma that
is limited to the liver. A 5-year survival rate of
70% can be achieved in such cases.10,11 However,
for patients with unresectable hepatoblastoma,
neoadjuvant chemotherapy is the only means to
convert them into resectable tumors, through
down-staging of the tumors.
In our study, perioperative mortality in the early
surgical era and the development of pulmonary
metastasis had an ominous impact on survival
outcome compared to other study groups.12,13
However, with the advent of efficacious chemo-
therapy, survival has improved as compared to
an early study in Taiwan.14 It is noteworthy that
patients in our group had satisfactory results at
early follow-up. Complete tumor resection is a
prerequisite for cure, therefore, any strategy that
leads to an increased resection rate will result 
in improved survival.15 Reoperation for positive
resection margins does not necessarily have to be
performed, because postoperative chemotherapy
shows good results.1
Surgical removal of hepatoblastoma is never
easy, and resection-related deaths still occur even
with experienced surgeons.16 The introduction 
of chemotherapy to the neoadjuvant setting has
helped to improve surgical resection rates.17–20
Our data also support an important role for pre-
operative neoadjuvant chemotherapy if the tumor
is inoperable, or if the tumor is unlikely to undergo
gross total resection at initial diagnosis.
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